ECSP034714A - Moleculas de enlace terapeuticas - Google Patents
Moleculas de enlace terapeuticasInfo
- Publication number
- ECSP034714A ECSP034714A EC2003004714A ECSP034714A ECSP034714A EC SP034714 A ECSP034714 A EC SP034714A EC 2003004714 A EC2003004714 A EC 2003004714A EC SP034714 A ECSP034714 A EC SP034714A EC SP034714 A ECSP034714 A EC SP034714A
- Authority
- EC
- Ecuador
- Prior art keywords
- ser
- asn
- ile
- thr
- tyr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Las moléculas que comprende cuando menos un sitio de enlace de antígeno, la cual comprende, en la secuencia, las regiones hipervariables CDR1, CRD2 Y CRD3, teniendo la CRD1 la secuencia de aminoácidos Asn-Tyr-Ile-Ile-His (NYIH), teniendo la CDR1 la secuencia de aminoácidos Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) y teniendo la CDR3 la secuencia de aminoácidos Ser-Gly- Pro- Tyr - Ala-Trp-Phe-Asp-Thr (SPYAWFDT); por ejemplo, que comprende además en la secuencia. las regiones hipervariables CDR1', CDR2', Y CRD3', teniendo la CDR' la secuencia de aminoácidos Arg. Ala, Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (8rasqnigtsiq), teniendo la CDR1? la secuencia de aminoácidos Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSE-SIS), y teniendo la CDR3' la secuencia de aminoácidos Gln, Gln, Ser, Asn, Thr, Trp-Pro-Phe-Thr (QQSNTWPFT), por ejemplo un anticuerpo quimérico o humanizado, útil como un producto farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0103389.3A GB0103389D0 (en) | 2001-02-12 | 2001-02-12 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034714A true ECSP034714A (es) | 2003-09-24 |
Family
ID=9908539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004714A ECSP034714A (es) | 2001-02-12 | 2003-08-06 | Moleculas de enlace terapeuticas |
Country Status (26)
Country | Link |
---|---|
US (1) | US20040096901A1 (es) |
EP (1) | EP1421191B1 (es) |
JP (2) | JP2004533816A (es) |
KR (1) | KR100752029B1 (es) |
CN (1) | CN100529074C (es) |
AR (1) | AR035539A1 (es) |
AT (1) | ATE526409T1 (es) |
BR (1) | BR0207151A (es) |
CA (1) | CA2437963A1 (es) |
CZ (1) | CZ20032129A3 (es) |
EC (1) | ECSP034714A (es) |
ES (1) | ES2374554T3 (es) |
GB (1) | GB0103389D0 (es) |
HK (1) | HK1071769A1 (es) |
HU (1) | HUP0401560A3 (es) |
IL (1) | IL157136A0 (es) |
MX (1) | MXPA03007197A (es) |
NO (1) | NO20033549L (es) |
NZ (1) | NZ548865A (es) |
PE (1) | PE20020871A1 (es) |
PL (1) | PL369516A1 (es) |
RU (2) | RU2405790C2 (es) |
SK (1) | SK10082003A3 (es) |
TW (1) | TWI332524B (es) |
WO (1) | WO2002072832A2 (es) |
ZA (1) | ZA200305911B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050069538A1 (en) | 2003-09-18 | 2005-03-31 | Gregorio Aversa | Therapeutic binding molecules |
US7460960B2 (en) * | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
US7618788B2 (en) * | 2002-05-10 | 2009-11-17 | Millipore Corporation | Proteome epitope tags and methods of use thereof in protein modification analysis |
PL1664122T3 (pl) * | 2003-09-18 | 2010-08-31 | Novartis Ag | Terapeutyczne humanizowane przeciwciała przeciw izoformom CD45 |
JP5805358B2 (ja) | 2005-02-02 | 2015-11-04 | ブルース・ミルネ・ホール | 特異抗原に活性化したcd4+、cd25+t細胞 |
FR2892724B1 (fr) * | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii. |
US7855057B2 (en) * | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
US8569059B2 (en) | 2006-08-02 | 2013-10-29 | Newsouth Innovations Pty Limited | Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8 |
CA2689570A1 (en) * | 2007-06-05 | 2008-12-11 | Novartis Ag | Induction of tolerogenic phenotype in mature dendritic cells |
CN102686733A (zh) * | 2009-10-16 | 2012-09-19 | 陶氏益农公司 | 树枝状聚合物纳米技术用于将生物分子投递入植物细胞中的用途 |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
EP2502631A1 (en) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
KR20230087552A (ko) | 2020-10-15 | 2023-06-16 | 유씨비 바이오파마 에스알엘 | Cd45를 다량체화하는 결합 분자 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
WO1995025167A1 (en) * | 1994-03-17 | 1995-09-21 | Merck Patent Gmbh | Anti-egfr single-chain fvs and anti-egfr antibodies |
JPH09191886A (ja) * | 1996-01-19 | 1997-07-29 | Asahi Breweries Ltd | ヒト高親和性IgE受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体 |
-
2001
- 2001-02-12 GB GBGB0103389.3A patent/GB0103389D0/en not_active Ceased
-
2002
- 2002-02-08 TW TW091102431A patent/TWI332524B/zh not_active IP Right Cessation
- 2002-02-11 RU RU2008100239/10A patent/RU2405790C2/ru not_active IP Right Cessation
- 2002-02-11 PE PE2002000106A patent/PE20020871A1/es not_active Application Discontinuation
- 2002-02-11 AT AT02711860T patent/ATE526409T1/de not_active IP Right Cessation
- 2002-02-11 EP EP02711860A patent/EP1421191B1/en not_active Expired - Lifetime
- 2002-02-11 CZ CZ20032129A patent/CZ20032129A3/cs unknown
- 2002-02-11 KR KR1020037010584A patent/KR100752029B1/ko not_active IP Right Cessation
- 2002-02-11 SK SK1008-2003A patent/SK10082003A3/sk unknown
- 2002-02-11 NZ NZ548865A patent/NZ548865A/en unknown
- 2002-02-11 US US10/467,546 patent/US20040096901A1/en not_active Abandoned
- 2002-02-11 IL IL15713602A patent/IL157136A0/xx not_active IP Right Cessation
- 2002-02-11 ES ES02711860T patent/ES2374554T3/es not_active Expired - Lifetime
- 2002-02-11 MX MXPA03007197A patent/MXPA03007197A/es active IP Right Grant
- 2002-02-11 BR BR0207151-7A patent/BR0207151A/pt not_active IP Right Cessation
- 2002-02-11 WO PCT/EP2002/001420 patent/WO2002072832A2/en active Application Filing
- 2002-02-11 RU RU2003126168/13A patent/RU2328506C2/ru not_active IP Right Cessation
- 2002-02-11 CN CNB028047850A patent/CN100529074C/zh not_active Expired - Fee Related
- 2002-02-11 AR ARP020100448A patent/AR035539A1/es active IP Right Grant
- 2002-02-11 HU HU0401560A patent/HUP0401560A3/hu unknown
- 2002-02-11 PL PL02369516A patent/PL369516A1/xx not_active Application Discontinuation
- 2002-02-11 JP JP2002571886A patent/JP2004533816A/ja not_active Withdrawn
- 2002-02-11 CA CA002437963A patent/CA2437963A1/en not_active Abandoned
-
2003
- 2003-07-31 ZA ZA200305911A patent/ZA200305911B/en unknown
- 2003-08-06 EC EC2003004714A patent/ECSP034714A/es unknown
- 2003-08-11 NO NO20033549A patent/NO20033549L/no unknown
-
2005
- 2005-05-30 HK HK05104488.6A patent/HK1071769A1/xx not_active IP Right Cessation
-
2008
- 2008-09-08 JP JP2008229759A patent/JP2009034108A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP034714A (es) | Moleculas de enlace terapeuticas | |
TNSN06087A1 (en) | Therapeutic binding molecules | |
CY1124289T1 (el) | Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7 | |
HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
BR0112086A (pt) | Anticorpos para mcp-1 humano | |
HRP20020693B1 (en) | HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE | |
SG156547A1 (en) | Human monoclonal antibodies to ctla-4 | |
GEP20074222B (en) | Antibodies to cd40 | |
EP2377555A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
RS54088B1 (en) | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
WO2004094473A3 (en) | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) | |
NO20033718D0 (no) | Syntetiske humane peptider og farmasöytiske sammensetninger omfattende disse for behandling av systemisk lupus erythematosus | |
AU5728699A (en) | Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases | |
TH53112A (th) | สารภูมิต้านทานของมนุษย์ต่อ cd154 | |
TH53886A (th) | แอนติบอดี้ต่อ il-1b ในมนุษย์ |